Synlogic Inc (SYBX) to Post Q1 2019 Earnings of ($0.71) Per Share, Jefferies Financial Group Forecasts

Synlogic Inc (NASDAQ:SYBX) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Synlogic in a research note issued on Tuesday, April 30th, Zacks Investment Research reports. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will post earnings per share of ($0.71) for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $18.00 target price on the stock. Jefferies Financial Group also issued estimates for Synlogic’s Q2 2019 earnings at ($0.64) EPS, Q3 2019 earnings at ($0.63) EPS, Q4 2019 earnings at ($0.63) EPS, FY2019 earnings at ($2.61) EPS, FY2020 earnings at ($2.86) EPS, FY2021 earnings at ($2.56) EPS, FY2022 earnings at ($2.88) EPS and FY2023 earnings at ($1.05) EPS.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.03. Synlogic had a negative net margin of 2,005.43% and a negative return on equity of 38.93%. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.42 million.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Synlogic from a “buy” rating to a “hold” rating in a report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Synlogic in a research note on Tuesday, March 12th. Finally, BTIG Research initiated coverage on shares of Synlogic in a research note on Tuesday, February 12th. They issued a “buy” rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $18.84.

SYBX stock traded down $0.12 during mid-day trading on Thursday, reaching $8.18. 17,385 shares of the stock traded hands, compared to its average volume of 63,373. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.53 and a quick ratio of 11.53. Synlogic has a 52 week low of $5.75 and a 52 week high of $14.59. The stock has a market capitalization of $209.71 million, a price-to-earnings ratio of -4.03 and a beta of 2.40.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its stake in shares of Synlogic by 4.6% in the first quarter. Wells Fargo & Company MN now owns 28,411 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 1,245 shares during the period. Northern Trust Corp lifted its stake in shares of Synlogic by 1.2% in the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after buying an additional 2,005 shares during the period. Legal & General Group Plc bought a new stake in shares of Synlogic in the third quarter valued at about $33,000. Alps Advisors Inc. lifted its stake in Synlogic by 4.5% during the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock worth $467,000 after purchasing an additional 2,658 shares during the period. Finally, State of Wisconsin Investment Board lifted its stake in Synlogic by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 20,900 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 4,800 shares during the period. Institutional investors and hedge funds own 81.12% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: Market Capitalization in the Stock Market

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.